⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara Nigel G. Maher Alison J. Potter Elizabeth C. Paver Jordan W. Conway Serigne Lo Andrew J. Colebatch Georgina V. Long James S. Wilmott Richard A. Scolyer

View Full Paper

Ask AI

Bookmark

Share

Key Points

The analysis highlights significant differences in mutational load distribution between melanomas and nevi.
A notable correlation exists between mutational load and pathological features such as tumor thickness.
LOESS regression indicates varying mutational load models over age at biopsy for both melanoma and nevi instances.
The study provides evidence that mutational load can assist in understanding malignancy in melanocytic tumors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis reveals mutational load patterns in primary melanocytic tumors, suggesting implications for malignancy assessment.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5f5 https://doi.org/10.1158/1078-0432.30029231

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
2Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
3Table S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
4Table S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
5Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
6Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
7Figure S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
8Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025